Abstract
Rho family GTPases are known to be involved in cytoskeletal reorganization. We examined the possibility that these functions may be dictated by a balance of Rho family GTPase signaling. Using transient viral expression of RhoA, Rac1, Cdc42 and their mutants, as well as C3 exoenzyme, we altered cytoskeletal organization under normal growth conditions. Overexpression of wild-type or constitutively active forms of the Rho family GTPases led to their respective activation phenotypes. Overexpression of dominant negative forms of given Rho family GTPases led to a phenotype consistent with activation of the other Rho family GTPase. Treatment with C. difficile toxin A, that inactivates all Rho family GTPases, led to the transient appearance of a variety of activation phenotypes. Previously, we reported that inactivation of Rho led to induction of apoptosis, implying that Rho may play an important role in cell survival signaling. This signaling, however, is not affected by expression of any forms of Rac1 or Cdc42, and only inactivation of Rho led to induction of apoptosis. Rho family GTPases appear to coordinate cytoskeletal organization by a balance of signaling, while cell survival is regulated by a distinct Rho-mediated signaling pathway.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Avraham H and Weinberg RA. . 1989 Mol. Cell. Biol. 9: 2058–2066.
Bobak D, Moorman J, Guanzon A, Gilmer L and Hahn C. . 1997 Oncogene 15: 2179–2189.
Boguski MS and McCormick F. . 1993 Nature 366: 643–654.
Chaves-Olarte E, Weidmann M, von Eichel-Streiber C, Thelestam M. . 1997 J. Clin. Invest. 100: 1734–1741.
Chuang T, Hahn K, Lee J, Danley DE and Bokoch GM. . 1997 Mol. Biol. Cell. 8: 1687–1698.
Fiorentini C and Thelestam M. . 1991 Toxicon 29: 543–567.
Galandrini R, Henning SW and Cantrell DA. . 1997 Immunity 7: 163–174.
Gomez J, Martinez-A C, Giry M, Garcia A and Rebollo A. . 1997 Eur. J. Immunol. 27: 2793–2799.
Gulbins E, Coggeshall KM, Brenner B, Schlottmann K, Linderkamp O and Lang F. . 1996 J. Biol. Chem. 271: 26389–26394.
Hahn CS, Hahn YS, Braciale TJ and Rice CM. . 1992 Proc. Natl. Acad. Sci. USA 89: 2679–2683.
Hall A and Zerial M. . 1995 In Guidebook to the small GTPases Zerial M and Huber LA, (eds).. Oxford University Press Inc.: New York. 3–11.
Henning SW, Galandrini R, Hall A and Cantrell DA. . 1997 EMBO J. 16: 2397–2407.
Hill CS, Wynne J and Treisman R. . 1995 Cell 81: 1159–1170.
Just I, Wilm M, Selzer J, Rex G, von Eichel-Streiber C, Mann M and Aktories K. . 1995 J. Biol. Chem. 270: 13932–13936.
Kozma R, Ahmed S, Best A and Lim L. . 1995 Mol. Cell. Biol. 15: 1942–1952.
Kozma R, Sarner S, Ahmed S and Lim L. . 1997 Mol. Cell. Biol. 17: 1201–1211.
Li G, C D'Souza-Schore, Barbieri MA, Cooper JA and Stahl PD. . 1997 J. Biol. Chem. 272: 10337–10340.
Lim L, Manser E, Leung T and Hall C. . 1996 Eur. J. Biochem. 242: 171–185.
Lores P, Morin L, Luna R and Gacon G. . 1997 Oncogene 15: 601–605.
Manser E, Huang H, Loo T, Chen X, Dong J, Leung T and Lim L. . 1997 Mol. Cell. Biol. 17: 1129–1143.
Matsui T, Amano M, Yamamota T, Chihara K, Nakafuku M, Ito M, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K. . 1996 EMBO J. 15: 2208–2216.
Moorman JP, Bobak DA and Hahn CS. . 1996 J. Immunol. 156: 4146–4153.
Nobes CD, Lauritzen I, Mattei M-G, Paris S, Hall A, Chardin P. . 1998 J. Cell. Biol. 141: 187–197.
Nobes CD and Hall A. . 1995 Cell 81: 53–62.
Prendergast GC, Khosravi-Far R, Solski PA, Kurzawa H, Lebowitz PF and Der CJ. . 1995 Oncogene 10: 2289–2296.
Ridley AJ and Hall A. . 1992 Cell 70: 389–399.
Ridley AJ, Paterson HF, Johnston CL, Diekmann D and Hall A. . 1992 Cell 70: 401–410.
Roux P, Gauthier-Rouviere C, Doucet-Brutin S and Fort P. . 1997 Curr. Biol. 7: 629–637.
Schwartz MA, Schaller MD and Ginsberg MH. . 1995 Annu. Rev. Cell. Dev. Biol. 11: 549–600.
Szamel M and Resch K. . 1995 Eur. J. Biochem. 228: 1–15.
Thelestam M and Florin I. . 1984 J. Toxicol. Toxin Rev. 3: 139–180.
Wei Y, Zhang Y, Derewenda U, Liu X, Minor W, Nakamoto RK, Somlyo AV, Somlyo AP and Derewenda ZS. . 1997 Nature Struct. Biol. 4: 699–703.
Zigmond SH. . 1996 Curr. Opin. Cell. Biol. 8: 66–73.
Acknowledgements
This work was supported by research grants from the DHHS/NIH: GM54572 (DB and CH), AI33434 (CH), AI01478 (JM).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Moorman, J., Luu, D., Wickham, J. et al. A balance of signaling by Rho family small GTPases RhoA, Rac1 and Cdc42 coordinates cytoskeletal morphology but not cell survival. Oncogene 18, 47–57 (1999). https://doi.org/10.1038/sj.onc.1202262
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202262
Keywords
This article is cited by
-
SDF-1alpha concentration dependent modulation of RhoA and Rac1 modifies breast cancer and stromal cells interaction
BMC Cancer (2015)
-
Merlin isoform 2 in neurofibromatosis type 2–associated polyneuropathy
Nature Neuroscience (2013)
-
The small GTPase RhoA, but not Rac1, is essential for conditioned aversive memory formation through regulation of actin rearrangements in rat dorsal hippocampus
Acta Pharmacologica Sinica (2013)
-
RhoC GTPase is required for PC-3 prostate cancer cell invasion but not motility
Oncogene (2006)
-
The gene for a new brain specific RhoA exchange factor maps to the highly unstable chromosomal region 1p36.2–1p36.3.
Oncogene (2001)